Is fatigue and sleepiness common with atomoxetine (Strattera)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Fatigue/Sleepiness Common with Atomoxetine?

Yes, fatigue and somnolence are among the most common adverse effects of atomoxetine, occurring in approximately 8% and 11% of pediatric patients respectively, making them significantly more frequent than with placebo. 1

Frequency and Clinical Significance

  • Fatigue occurs in 8% of children and adolescents treated with atomoxetine compared to 3% with placebo 1
  • Somnolence (sleepiness) occurs in 11% of pediatric patients versus 4% with placebo 1
  • These are listed among the most common adverse effects alongside nausea, vomiting, decreased appetite, and abdominal pain 1
  • The FDA drug label specifically identifies both fatigue and somnolence as common treatment-emergent adverse reactions occurring at ≥2% incidence and greater than placebo 2

Important Clinical Context

Initial vs. Sustained Effects

  • "Initial somnolence" is specifically noted as a common side effect, particularly if the dosage is increased too rapidly 1
  • This suggests the sedating effects may be most prominent early in treatment or with rapid dose escalation 1

Poor Metabolizers at Higher Risk

  • Patients who are CYP2D6 poor metabolizers (approximately 7% of the population) experience significantly higher plasma levels and longer half-lives of atomoxetine 1
  • Poor metabolizers show statistically significantly higher rates of sedation (4%) compared to extensive metabolizers (2%) 2
  • This population may experience an increase in adverse effects including fatigue and somnolence 1

Comparison to Stimulants

  • Atomoxetine causes more somnolence than stimulant medications 3
  • Conversely, stimulants cause more insomnia than atomoxetine 3
  • This makes atomoxetine particularly useful for patients with ADHD who experience sleep disturbances on stimulants 4

Practical Management Strategies

Dosing Adjustments

  • Split dosing (morning and evening) can reduce side effects including sedation 4
  • Slow titration is critical - adjust doses every 7-14 days to minimize initial somnolence 1, 2
  • Consider evening dosing if daytime sedation is problematic 4

When to Expect Improvement

  • Sedating effects are typically most prominent during initial treatment phases 1
  • Full therapeutic effects take 6-12 weeks to develop, and tolerability may improve during this period 4

Common Pitfall to Avoid

Do not increase the dose too rapidly - this is specifically associated with increased somnolence and gastrointestinal symptoms 1. The recommended titration schedule of 7-14 days between dose adjustments should be followed 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Atomoxetine for ADHD Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.